Article Text

other Versions

PDF
Response of refractory ITP in a patient with common variable immunodeficiency (CVID) to treatment with rituximab
  1. Tariq M El-Shanawany (tariq.el-shanawany{at}cardiffandvale.wales.nhs.uk)
  1. University Hospital Wales, United Kingdom
    1. Paul E Williams
    1. University Hospital Wales, United Kingdom
      1. Stephen Jolles (stephen.jolles{at}cardiffandvale.wales.nhs.uk)
      1. University Hospital Wales, United Kingdom

        Abstract

        CVID is the commonest serious antibody deficiency in adults. There are a number of associated complications including autoimmunity, of which immune thrombocytopenic purpura (ITP) is a relatively common example. ITP usually responds to treatment with corticosteroids, other immunosuppression, splenectomy or high dose intravenous immunologlobulin (IVIG). The management of ITP refractory to these treatments remains challenging. We report a patient with CVID who developed ITP and remained platelet transfusion dependent despite high dose IVIG and splenectomy. Treatment with rituximab resulted in normalisation of the platelet count and the patient remains transfusion independent at one year following rituximab therapy.

        • common variable immunodeficiency
        • idiopathic thrombocytopenic purpura
        • rituximab

        Statistics from Altmetric.com

        Request permissions

        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.